Fundz

Passage Bio, Inc. reported raising $110 Million in an initial SEC Form D filing, from an offering of $110 Million

PUBLIC · PASGSep 06, 2019$110M of $110M raised

Amount Raised

$110 Million

$110 Million sold, per SEC Form D (first sale Sep 6, 2019)

Round Type

Venture

United StatesBiotechnologyHealthcareHealth CareGeneticsTherapeutics

Quick answer

Passage Bio raised $110 Million in a funding round, dated September 6, 2019. Passage Bio is based in United States.

How much did Passage Bio raise?
Passage Bio raised $110 Million in a funding round on September 6, 2019.
What does Passage Bio do?
Passage Bio, Inc. (NASDAQ: PASG) is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases.
Where is Passage Bio based and how big is it?
Passage Bio is based in United States. Fundz records about 83 employees.
Who are the decision-makers at Passage Bio?
Fundz holds 1 contact at Passage Bio, including the Chief Executive Officer. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Healthcare and Genetics around the same time

Companies in the same sectors as Passage Bio that raised within 45 days of this round, from Fundz verified event records.

  • Solid Biosciences raised $60M on July 31, 2019.
  • Renovacor, Inc. raised $3.8M (Seed) on October 15, 2019.
  • vTv Therapeutics Inc. raised $2M (Seed) on October 15, 2019.
  • Immuneering raised $20M on October 4, 2019.
  • Geneoscopy raised $7.9M on September 30, 2019.
  • Renibus Therapeutics raised $3.4M on September 23, 2019.

Who to call at Passage Bio, and when

A new round usually means Passage Bio is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Passage Bio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Passage Bio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Passage Bio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Passage Bio

Location

United States

About

Passage Bio, Inc. (NASDAQ: PASG) is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Passage Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsWill C., Chief Executive Officer hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Passage Bio's next move

See what Strategic adds

Passage Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.